MET-097 is a glucagon-like peptide 1 receptor (GLP-1R) agonist developed at Metsera for treating overweight and obesity and is currently in phase II clinical trials.

The city needs a new sports stadium for student athletes, but that can be done for about $20 million. Imagine what could be ...

New Iowa laws on issues from transgender civil rights protections to changes to Iowa’s unemployment insurance tax system will ...

The FDA has accepted Aquestive Therapeutics’ new drug application for its Anaphylm sublingual epinephrine film for treating ...

We've tried to do everything we can for him, but nothing changes for long and the cycle starts all over again.

After 35 years, the Pediatric Interim Care Center in Kent – the only specialized medical facility in western Washington ...

The FDA’s clunky launch of Elsa, an AI tool to increase efficiency, has sparked concern from agency employees and outside ...

Curay, MD, acting director of the FDA’s Center for Drug Evaluation and Research, will step down in July after more than eight years at the agency, Bloomberg Law reported June 23. In an internal email ...

The FDA's new AI assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

Curay, the FDA’s acting top drug regulator, is stepping down from her post after serving at the agency for more than eight ...

Report is The Hill’s midday newsletter. Subscribe here or using the box below: Happy Friday! The summer solstice is tonight! 🍦 Did anyone capture any cool photos or videos of ...

The FDA didn’t routinely test the medications for quality problems or use its vast repository of drug-related complaints to proactively track whether they were harming the people who relied on them.